Page 73 - Read Online

Page 162 Shad. J Transl Genet Genom 2023;7:141-65 https://dx.doi.org/10.20517/jtgg.2023.11

86. Yu YW, Tsai SJ, Yang KH, Lin CH, Chen MC, Hong CJ. Evidence for an association between polymorphism in the serotonin-2A
receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine. Neuropsychobiology
2001;43:79-82. DOI PubMed
87. Brandl EJ, Lett TA, Chowdhury NI, et al. The role of the ITIH3 rs2535629 variant in antipsychotic response. Schizophr Res
2016;176:131-5. DOI
88. Ikeda M, Yoshimura R, Hashimoto R, et al. Genetic overlap between antipsychotic response and susceptibility to schizophrenia. J
Clin Psychopharmacol 2015;35:85-8. DOI
89. Adkins DE, Aberg K, McClay JL, et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol
Psychiatry 2011;16:321-32. DOI PubMed PMC
90. With SAJ, Pulit SL, Staal WG, Kahn RS, Ophoff RA. More than 25 years of genetic studies of clozapine-induced agranulocytosis.
Pharmacogenomics J 2017;17:304-11. DOI PubMed
91. Lally J, Malik S, Whiskey E, et al. Clozapine-associated agranulocytosis treatment with granulocyte colony-stimulating factor/
granulocyte-macrophage colony-stimulating factor: a systematic review. J Clin Psychopharmacol 2017;37:441-6. DOI
92. la Chapelle A, Kari C, Nurminen M, Hernberg S. Clozapine-induced agranulocytosis. A genetic and epidemiologic study. Hum Genet
1977;37:183-94. DOI PubMed
93. Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P. Agranulocytosis in patients treated with clozapine. A study of the Finnish
epidemic. Acta Psychiatr Scand 1977;56:241-8. DOI PubMed
94. Clark SR, Warren NS, Kim G, et al. Elevated clozapine levels associated with infection: a systematic review. Schizophr Res
2018;192:50-6. DOI
95. Ruan CJ, Zhen XY, Ge XL, et al. Pneumonia can cause clozapine intoxication: a case report. Psychosomatics 2017;58:652-6. DOI
96. Wagner A, Shad MU. Relationship between clozapine levels and acute inflammatory stress. Prim Care Companion CNS Disord
2020;22:19br02586. DOI PubMed
97. Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia.
Eur J Clin Pharmacol 2000;56:585-9. DOI PubMed
98. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry
Neurosci 2003;28:99-112. PubMed PMC
99. Ruan CJ, de Leon J. Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine? Pharmacogenomics
2020;21:369-73. DOI
100. Buur-Rasmussen B, Brøsen K. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur
Neuropsychopharmacol 1999;9:453-9. DOI PubMed
101. Dettling M, Sachse C, Müller-Oerlinghausen B, et al. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine
metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry 2000;33:218-20. DOI
102. Røge R, Møller BK, Andersen CR, Correll CU, Nielsen J. Immunomodulatory effects of clozapine and their clinical implications:
what have we learned so far? Schizophr Res 2012;140:204-13. DOI PubMed
103. Taylor D, Vallianatou K, Whiskey E, Dzahini O, MacCabe J. Distinctive pattern of neutrophil count change in clozapine-associated,
life-threatening agranulocytosis. Schizophrenia 2022;8:21. DOI PubMed PMC
104. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12760 clozapine recipients in the UK
and Ireland. Br J Psychiatry 1999;175:576-80. DOI
105. Riecher-Rössler A. [50 years after Manfred Bleuler. what do we know today about late-onset schizophrenia(s)?] Nervenarzt
1997;68:159-70. DOI PubMed
106. Dettling M, Cascorbi I, Roots I, Mueller-Oerlinghausen B. Genetic determinants of clozapine-induced agranulocytosis: recent results
of HLA subtyping in a non-jewish caucasian sample. Arch Gen Psychiatry 2001;58:93-4. DOI
107. Deliliers G. Blood dyscrasias in clozapine-treated patients in Italy. Haematologica 2000;85:233-7. PubMed
108. Stübner S, Grohmann R, Engel R, et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004;37 Suppl 1:S70-
8. DOI
109. Demler TL, Morabito NE, Meyer CE, Opler L. Maximizing clozapine utilization while minimizing blood dyscrasias: evaluation of
patient demographics and severity of events. Int Clin Psychopharmacol 2016;31:76-83. DOI PubMed
110. Hollingworth SA, Winckel K, Saiepour N, Wheeler AJ, Myles N, Siskind D. Correction to: clozapine-related neutropenia,
myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014. Psychopharmacology 2018;235:2193. DOI PubMed
111. Tunsirimas N, Pariwatcharakul P, Choovanichvong S, Ratta-Apha W. Clozapine-induced agranulocytosis and leukopenia: incidence,
associated factors, and rate of hematologic adverse-effects monitoring in psychiatric out-patient services in Thailand. Asian J
Psychiatr 2019;41:13-6. DOI PubMed
112. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in
the United States. N Engl J Med 1993;329:162-7. DOI PubMed
113. Wellesley Wesley E, Patel I, Kadra-Scalzo G, et al. Gender disparities in clozapine prescription in a cohort of treatment-resistant
schizophrenia in the South London and Maudsley case register. Schizophr Res 2021;232:68-76. DOI
114. Horáček J, Libiger J, Höschl C, Borzova K, Hendrychová I. Clozapine-induced concordant agranulocytosis in monozygotic twins. Int
J Psychiatry Clin Pract 2001;5:71-3. DOI PubMed
115. Yağcıoğlu AE, İlhan BÇ, Göktaş MT, Babaoğlu MO, Uz E, Yazıcı MK. Agranulocytosis related to clozapine in monozygotic twins